Last reviewed · How we verify
Benova (Tianjin) Innovative medicine Research Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Fosfomycin Tromethamine Granules | Fosfomycin Tromethamine Granules | phase 3 | Antibiotic (phosphonic acid derivative) | MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) | Infectious Disease | |
| Pivmecillinam hydrochloride tablets | Pivmecillinam hydrochloride tablets | phase 3 | Beta-lactam antibiotic | Penicillin-binding proteins (PBPs) | Infectious diseases |
Therapeutic area mix
- Infectious Disease · 1
- Infectious diseases · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Bayer · 1 shared drug class
- Belén Retamal-Valdes · 1 shared drug class
- Esraa Salah Mohamed Abdallah Eladl · 1 shared drug class
- Incheon St.Mary's Hospital · 1 shared drug class
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 shared drug class
- KEMRI-Wellcome Trust Collaborative Research Program · 1 shared drug class
- National Taiwan University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Benova (Tianjin) Innovative medicine Research Co., Ltd.:
- Benova (Tianjin) Innovative medicine Research Co., Ltd. pipeline updates — RSS
- Benova (Tianjin) Innovative medicine Research Co., Ltd. pipeline updates — Atom
- Benova (Tianjin) Innovative medicine Research Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Benova (Tianjin) Innovative medicine Research Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/benova-tianjin-innovative-medicine-research-co-ltd. Accessed 2026-05-17.